

CONTENTS

NOTE TO THE READER	5
LIST OF PARTICIPANTS	7
PREAMBLE	
Background	11
Objective and Scope	11
Selection of Topics for Monographs	12
Data for Monographs	13
The Working Group	13
Working Procedures	14
Exposure Data	14
Biological Data Relevant to the Evaluation of Carcinogenicity to Humans	16
Evidence for Carcinogenicity in Experimental Animals	17
Other Relevant Data in Experimental Systems and in Humans	19
Evidence for Carcinogenicity in Humans	21
Summary of Data Reported	24
Evaluation	25
References	29
GENERAL REMARKS	33
THE MONOGRAPHS	
Antineoplastic and immunosuppressive agents	
Azacitidine	47
Chlorozotocin	65
Ciclosporin	77
Prednimustine	115
Thiotepa	123
Trichlormethine (Trimustine hydrochloride)	143

CONTENTS

Antimicrobial agents

Ampicillin	153
Chloramphenicol	169
Nitrofurantoin (Nitrofurazone)	195
Nitrofurantoin	211

Other drugs

Cimetidine	235
Dantron (Chrysazin; 1,8-Dihydroxyanthraquinone)	265
Furosemide (Frusemide)	277
Hydrochlorothiazide	293
Paracetamol (Acetaminophen)	307

SUMMARY OF FINAL EVALUATIONS	333
------------------------------------	-----

APPENDIX 1. SUMMARY TABLE OF GENETIC AND RELATED EFFECTS	335
--	-----

APPENDIX 2. ACTIVITY PROFILES FOR GENETIC AND RELATED EFFECTS	337
---	-----

SUPPLEMENTARY CORRIGENDA TO VOLUMES 1-49	385
--	-----

CUMULATIVE INDEX TO THE <i>MONOGRAPHS</i> SERIES	387
--	-----

NOTE TO THE READER

The term 'carcinogenic risk' in the *IARC Monographs* series is taken to mean the probability that exposure to an agent will lead to cancer in humans.

Inclusion of an agent in the *Monographs* does not imply that it is a carcinogen, only that the published data have been examined. Equally, the fact that an agent has not yet been evaluated in a monograph does not mean that it is not carcinogenic.

The evaluations of carcinogenic risk are made by international working groups of independent scientists and are qualitative in nature. No recommendation is given for regulation or legislation.

Anyone who is aware of published data that may alter the evaluation of the carcinogenic risk of an agent to humans is encouraged to make this information available to the Unit of Carcinogen Identification and Evaluation, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France, in order that the agent may be considered for re-evaluation by a future Working Group.

Although every effort is made to prepare the monographs as accurately as possible, mistakes may occur. Readers are requested to communicate any errors to the Unit of Carcinogen Identification and Evaluation, so that corrections can be reported in future volumes.